Deregulation of miRNAs-cMYC circuits is a key event in refractory celiac disease type-2 lymphomagenesis

Area of Science:

• Oncology
• Immunology
• Genetics

Background:

• Refractory celiac disease type 2 (RCD2) increases enteropathy-associated T-cell lymphoma (EATL) risk, lacking effective treatments.
• MicroRNAs (miRNAs) play crucial roles in cellular processes and disease pathogenesis.
• Understanding miRNA dysregulation in RCD2 and EATL is vital for developing targeted therapies.

Purpose of the Study:

• To profile the miRNome in refractory celiac disease (RCD) and related T-cell lymphomas.
• To identify specific miRNA signatures associated with RCD2 and EATL.
• To investigate the role of miRNAs in oncogenic signaling pathways implicated in RCD2 lymphomagenesis.

Main Methods:

• miRNome profiling of peripheral T-cell lymphomas (PTCLs), celiac disease (CD), RCD1/2, and a murine IL15-transgenic (TG) model.
• Transcriptome analysis of 18 intestinal T-cell lymphomas (ITLs).
• Bioinformatics analysis for miRNA identification and target prediction, validated in patient cohorts; random forest algorithm for miRNA signature identification.

Main Results:

• Intestinal T-cell lymphomas (ITLs) exhibit distinct miRNA profiles compared to other PTCLs.
• The c-MYC regulated miR-17/92 cluster differentiates monomorphic epitheliotropic ITL (MEITL) from EATL and predicts EATL outcomes.
• Loss of miR-200 and miR-192/215 families, with upregulation of miR-17/92 and C19MC miRNAs, observed in RCD2 and ITL-CD; associated with increased SMAD3, MDM2, c-Myc, and activated-STAT3 levels.

Conclusions:

• miRNA dysregulation contributes to STAT3 and c-Myc activation in RCD2, promoting lymphomagenesis.
• The identified miRNA signatures may serve as biomarkers for RCD2 and EATL.
• This research provides a foundation for developing novel, personalized therapeutic strategies targeting miRNA pathways in RCD2 and EATL.